Humana (HUM) to Release Quarterly Earnings on Wednesday

Humana (NYSE:HUM) is scheduled to be releasing its earnings data before the market opens on Wednesday, November 7th. Analysts expect Humana to post earnings of $4.30 per share for the quarter.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.79 by $0.17. The company had revenue of $14.26 billion during the quarter, compared to analyst estimates of $14.16 billion. Humana had a net margin of 2.48% and a return on equity of 17.43%. During the same quarter last year, the firm posted $3.49 earnings per share. On average, analysts expect Humana to post $14 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Shares of HUM stock opened at $323.50 on Wednesday. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.47. The stock has a market cap of $43.84 billion, a price-to-earnings ratio of 27.64, a P/E/G ratio of 1.59 and a beta of 0.97. Humana has a 1-year low of $231.90 and a 1-year high of $341.30.



The business also recently announced a quarterly dividend, which was paid on Friday, October 26th. Shareholders of record on Friday, September 28th were paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 0.62%. The ex-dividend date of this dividend was Thursday, September 27th. Humana’s dividend payout ratio (DPR) is presently 17.08%.

Several brokerages have weighed in on HUM. Cowen began coverage on shares of Humana in a research note on Monday, September 17th. They set a “market perform” rating and a $372.00 target price for the company. SunTrust Banks increased their target price on shares of Humana to $380.00 and gave the stock a “hold” rating in a research note on Wednesday, September 19th. Credit Suisse Group increased their target price on shares of Humana from $350.00 to $370.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 4th. Argus increased their target price on shares of Humana to $375.00 and gave the stock a “buy” rating in a research note on Tuesday, September 4th. Finally, Zacks Investment Research lowered shares of Humana from a “buy” rating to a “hold” rating in a research note on Friday, October 5th. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $339.79.

In other news, SVP Cynthia H. Zipperle sold 4,886 shares of the stock in a transaction dated Friday, August 3rd. The shares were sold at an average price of $321.89, for a total transaction of $1,572,754.54. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bruce D. Broussard sold 18,000 shares of the stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the sale, the chief executive officer now directly owns 71,085 shares in the company, valued at approximately $23,362,796.10. The disclosure for this sale can be found here. Insiders have sold 40,284 shares of company stock worth $13,147,715 in the last three months. Corporate insiders own 0.60% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Further Reading: Stock Symbols and CUSIP Explained

Earnings History for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply